DMD and gastrointestinal stromal tumor: Using genome-wide single nucleotide polymorphism (SNP) assays, Wang et al. found intragenic DMD deletions in 63% of high-grade myogenic cancers, including gastrointestinal stromal tumour (GIST), leiomyosarcoma (LMS) and RMS.